



October 7, 2016

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East,
Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

Sub: Issue of unsecured high yield bonds by our wholly-owned subsidiary Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933 (the “US Securities Act”).


Further to our letter dated October 6, 2016, where we have informed about the closure of the benchmark offering of rated unsecured high yield bonds (the “Notes”) in an aggregate principal amount of US\$300 million by our material wholly-owned subsidiary, Jubilant Pharma Limited, outside India, under Regulation S of the US Securities Act, we would like to inform that the Notes have been listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”) on October 7, 2016.

With this letter, we have also attached the Final Offering Memorandum filed with the SGX-ST in connection with the issuance of the Notes.

The above is for your information and records.

Thanking You,

Yours Sincerely,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624